Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruption
Benchmarks Nifty22,516.40-171.25FEATURED FUNDS★★★★★UTI Aggressive Hybrid Fund Regular Plan-Growth5Y Return8.69 % Invest NowFEATURED FUNDS★★★★★Motilal Oswal Midcap Fund Direct-Growth5Y Return18.25 % Invest NowEnter search…
Dr Reddy’s Laboratories has expanded its generic semaglutide portfolio with Obeda Pro and Obeda Plus after supplies of its original Obeda injection were halted in July for technical evaluation. The new brands are manufactured by Hetero Labs, while distributors say the company may discontinue Obeda injectable supplies. Dr Reddy’s denies a replacement strategy.
Hyderabad: Dr Reddy's Laboratories has expanded its portfolio of generic versions of Ozempic with two new brands, according to product photographs and marketing materials reviewed by Reuters, after supply disruptions hit sales of its original Obeda injection in India's fast-growing semaglutide market.Obeda Pro and Obeda Plus are made by a different manufacturer than the original Obeda injectable, supplies of which were halted in July after Dr Reddy's discovered an impurity in the active ingredient.
Also read: Dr Reddy's gets DCGI nod for Zytorvi in advanced esophageal cancer
Dr Reddy's is likely to discontinue supplies of Obeda and instead focus on Obeda Pro and Obeda Plus, several distributors told Reuters.
"The company said there were some technical issues with Obeda injectable, and they recalled stocks from us. They said they would instead supply Obeda Pro," a drug distributor said on condition of anonymity as they were not authorized to speak to the media.
Live Events
The development and launch planning for products such as Obeda Pro and Obeda Plus were under way well before the July supply disruption issues, Dr Reddy's said in response to a Reuters request for comment.
"The presence of multiple semaglutide brands and manufacturing arrangements reflects the breadth of our portfolio strategy and should not be interpreted as evidence that one product was launched to replace another," it said.
Dr Reddy's recalled Obeda injection in July "for technical evaluation," according to a notice reviewed by Reuters. The company did not reply to a Reuters question on whether the recall was related to the impurity. An oral version of the drug was not recalled.
Dr Reddy's launched Obeda - a generic version of Novo Nordisk's diabetes drug - in India in March after semaglutide lost patent protection in the country, setting off a race among domestic pharma companies to launch lower-cost versions of the drug.
Semaglutide, which suppresses appetite, is also the active ingredient in Novo's blockbuster weight-loss drug Wegovy.
Obeda Plus and Obeda Pro are available in different dose strengths, just like Ozempic and Wegovy.
Research firm Pharmarack estimated in March that the domestic market for semaglutide drugs will grow to 80 billion rupees ($843.99 million) by 2030.
Dr Reddy's said in July that supplies of Obeda injections would be unavailable until November. Analysts warned at the time that the company risked losing market share in India's increasingly competitive semaglutide market if supplies were not restored quickly. Dr Reddy's did not reply to a question on whether it had resolved the impurity issue.
Also read: Dr Reddy’s Laboratories receives two observations for Andhra Pradesh facility
Packaging materials reviewed by Reuters showed Obeda was manufactured by contract manufacturer OneSource Specialty Pharma . Obeda Pro and Obeda Plus, which began appearing in the market in late July according to supply invoices reviewed by Reuters, are manufactured by Hetero Labs.
Hetero Labs and OneSource Specialty Pharma did not respond to requests for comment.
Dr Reddy's sold about 442,000 units of generic semaglutide through September in India, according to research firm Pharmarack. By comparison, India's largest drugmaker Sun Pharma sold 151,000 semaglutide units.
Add as a Reliable and Trusted News Source Add Now!
(You can now subscribe to our Economic Times WhatsApp channel)
Read More News ononesource specialty pharmadr reddy's laboratoriesDr Reddy's Laboratoriesgeneric OzempicObeda ProObeda Plussemaglutide marketObeda recallNovo NordiskHetero Labs
(Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.)
...moreless(You can now subscribe to our Economic Times WhatsApp channel)
Read More News ononesource specialty pharmadr reddy's laboratoriesDr Reddy's Laboratoriesgeneric OzempicObeda ProObeda Plussemaglutide marketObeda recallNovo NordiskHetero Labs
(Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.)
...morelessContinue reading with one of these options:Limited AccessFreeLogin to get access to some exclusive stories& personalised newslettersLogin NowUnlimited AccessStarting @ Rs120/monthGet access to exclusive stories, expert opinions &
in-depth stock reportsSubscribe NowET
Unlock Access to All Exclusives with ETPrime FREE TRIAL
15 Days Free: Unlock All ETPrime Exclusives, Market Tools & ePapers
Trial offer expiring in00 : 05 : 00
I'd rather pay ₹2599 nowUh-oh! This is an exclusive story available for selected readers only.
Worry not. You’re just a step away.
Prime Account Detected!
It seems like you're already an ETPrime member with
Login using your ET Prime credentials to enjoy all member benefits
Log out of your current logged-in account and log in again using your ET Prime credentials to enjoy all member benefits.
Unlock ETPrime's Exclusive Stories Today!
Big Price Drop! Flat 40% Off
Student Only OfferAlready a Member? Sign In nowAlready a Member? Sign In nowAlready a Member? Sign In nowOffer Exclusively For You
Save up to Rs. 700/-
ON ET PRIME MEMBERSHIP
Avail OfferOffer Exclusively For You
Get 1 Year Free
With 1 and 2-Year ET prime membership
Avail OfferOffer Exclusively For You
Get 1 Year Free
With 1 and 2-Year ET prime membership
Avail OfferOffer Exclusively For You
Get Flat 40% Off
Then ₹ 1749 for 1 year
Avail OfferOffer Exclusively For You
ET Prime at ₹ 49 for 1 month
Then ₹ 1749 for 1 year
Avail OfferSpecial Offer
Get flat 40% off on ETPrime
Avail OfferAvail OfferClaim NowAlready a Member? Sign In nowNeed Assistance?
Connect with an ETPrime expert for personalized support and guidance
+91 9484700004'; }); } if(listing) { var h3 = "You tried reading " + listArr.length + " locked stories in the past " + threshold + " days.", h4 = "Become an ET Prime member and don't miss out on these exclusive stories."; var html = '' + h3 + '
' + h4 + '
- ' + listing + '
What’s Included with
ETPrime Membership
1Exclusive Insights That Matter
Uncover the truth with our investigative stories
Make strategic moves using the real-world case studies
Read industry-specific stories to identify emerging trends
Spot opportunities with in-depth insights that matter
Trump temper on H-1B visas is forcing Indians to do these things to stay put in US
What Adani’s US indictment means for India Inc’s overseas fundraising
Why veterans like Reliance, L&T are on acquisition spree? Aswath Damodaran has an answer.
Will China’s dollar bond sale in Saudi Arabia trump the US in financial world?
Huawei launches its own OS to compete with Google and Apple. But can it win beyond China?
The problem with lab grown diamonds
Why a falling rupee is a better option for the economy
A list of top 20 momentum stocks that have delivered massive returns in one year
2Invest Wisely With Smart Market Tools & Investment Ideas
Alpha Trade
Get daily trade ideas from SEBI-registered research analysts.
Investment Ideas
Grow your wealth with stock ideas & sectoral trends.
Stock Reports Plus
All-in-one stock research with Stock Score, peer comparison & key signals.
BigBull Portfolio
Get to know where the market bulls are investing to identify the right stocks.
Stock Analyzer
Check the score based on the company's fundamentals, solvency, growth, risk & ownership to decide the right stocks.
Market Mood
Analyze the market sentiments & identify the trend reversal for strategic decisions.
Stock Talk Live at 9 AM Daily
Ask your stock queries & get assured replies by ET appointed, SEBI registered experts.
3Stay informed anytime, anywhere with ET ePaper
ePaper - Print View
Read the PDF version of ET newspaper. Download & access it offline anytime.
ePaper - Digital View
Read your daily newspaper in Digital View & get it delivered to your inbox everyday.
Wealth Edition
Manage your money efficiently with this weekly money management guide.
TOI ePaper
Read the PDF version of TOI newspaper. Download & access it offline anytime.
Deep Explainers
Explore the In-depth explanation of complex topics for everyday life decisions.
Health+ Stories
Get fitter with daily health insights committed to your well-being.
Personal Finance+ Stories
Manage your wealth better with in-depth insights & updates on finance.
5Enjoy Complimentary Subscriptions From Top Brands
Stream new documentaries from all across the world every day.
Stories you might be interested in
Figures reflect the source report and its stated period. This article is for information and is not investment advice.
